{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:47:53Z","timestamp":1788346073071,"version":"build-2803163510"},"reference-count":91,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Immunology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.humimm.2024.111172","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T22:07:13Z","timestamp":1731103633000},"page":"111172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Antigen-specific immunotherapy for platelet alloimmune disorders"],"prefix":"10.1016","volume":"85","author":[{"given":"Debra K.","family":"Newman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humimm.2024.111172_b0005","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal Fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.humimm.2024.111172_b0010","first-page":"2677","article-title":"Fc receptors in immune thrombocytopenias: a target for immunomodulation?","volume":"118","author":"Psaila","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.humimm.2024.111172_b0015","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/ANC.0000000000000775","article-title":"Neonatal alloimmune thrombocytopenia: A concise review","volume":"21","author":"Norton","year":"2021","journal-title":"Adv Neonatal Care"},{"key":"10.1016\/j.humimm.2024.111172_b0020","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ajog.2021.04.211","article-title":"New developments in fetal and neonatal alloimmune thrombocytopenia","volume":"225","author":"Bussel","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.humimm.2024.111172_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2019.102704","article-title":"Epidemiology and management of fetal and neonatal alloimmune thrombocytopenia","volume":"59","author":"de Vos","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.humimm.2024.111172_b0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bjh.12235","article-title":"Neonatal alloimmune thrombocytopenia: Pathogenesis, diagnosis and management","volume":"161","author":"Peterson","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.humimm.2024.111172_b0035","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/bjh.13639","article-title":"Recent progress in understanding the pathogenesis of fetal and neonatal alloimmune thrombocytopenia","volume":"171","author":"Curtis","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.humimm.2024.111172_b0040","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/vox.12085","article-title":"Human platelet antigens - 2013","volume":"106","author":"Curtis","year":"2014","journal-title":"Vox Sang"},{"key":"10.1016\/j.humimm.2024.111172_b0045","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1515\/labmed-2020-0012","article-title":"Platelet antibodies in immune thrombocytopenia and related conditions","volume":"44","author":"Kiefel","year":"2020","journal-title":"J Lab Med"},{"key":"10.1016\/j.humimm.2024.111172_b0050","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1182\/bloodadvances.2020002137","article-title":"Fetal\/neonatal alloimmune thrombocytopenia: A systematic review of impact of HLA-DRB3*01:01 on fetal\/neonatal outcome","volume":"4","author":"Kjeldsen-Kragh","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.humimm.2024.111172_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.101038","article-title":"Fetal and neonatal alloimmune thrombocytopenia: Current pathophysiological insights and perspectives for future diagnostics and treatment","volume":"59","author":"Stam","year":"2023","journal-title":"Blood Rev"},{"key":"10.1016\/j.humimm.2024.111172_b0060","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1399-0039.1985.tb00936.x","article-title":"Immunogenicity of and immune response to the human platelet antigen Zwa is strongly associated with HLA-B8 and DR3","volume":"26","author":"Mueller-Eckhardt","year":"1985","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.humimm.2024.111172_b0065","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2141.1990.tb02567.x","article-title":"Alloimmunization due to the PlA1 platelet antigen: Results from a prospective study","volume":"74","author":"Blanchette","year":"1990","journal-title":"Br J Haematol."},{"key":"10.1016\/j.humimm.2024.111172_b0070","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-2141.1995.tb05152.x","article-title":"Antenatal screening for fetal alloimmune thrombocytopenia: The results of a pilot study","volume":"90","author":"Doughty","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1016\/j.humimm.2024.111172_b0075","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1055\/s-2007-994382","article-title":"Screening primiparous women and newborns for fetal\/neonatal alloimmune thrombocytopenia: A prospective comparison of effectiveness and costs","volume":"13","author":"Durand-Zaleski","year":"1996","journal-title":"Immune Thrombocytopenia Working Group, Am J Perinatol"},{"key":"10.1016\/j.humimm.2024.111172_b0080","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood.V92.7.2280","article-title":"The natural history of fetomaternal alloimmunization to the platelet- specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening","volume":"92","author":"Williamson","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.humimm.2024.111172_b0085","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.0042-9007.2003.00363.x","article-title":"Antenatal screening of unselected pregnant women for HPA-1a antigen, antibody and alloimmune thrombocytopenia","volume":"85","author":"Maslanka","year":"2003","journal-title":"Vox Sang"},{"key":"10.1016\/j.humimm.2024.111172_b0090","first-page":"492","article-title":"Antenatal screening for human platelet antigen-1a: Results of a prospective study at a large maternity hospital in Ireland","volume":"110","author":"Davoren","year":"2003","journal-title":"BJOG"},{"key":"10.1016\/j.humimm.2024.111172_b0095","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1111\/j.1537-2995.2005.00645.x","article-title":"Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a","volume":"45","author":"Turner","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.humimm.2024.111172_b0100","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2006-08-040121","article-title":"A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia","volume":"110","author":"Kjeldsen-Kragh","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.humimm.2024.111172_b0105","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.5114\/aoms.2016.63600","article-title":"Identification and follow-up of pregnant women with platelet-type human platelet antigen (HPA)-1bb alloimmunized with fetal HPA-1a","volume":"14","author":"Debska","year":"2018","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.humimm.2024.111172_b0110","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.4049\/jimmunol.158.7.3221","article-title":"An integrin polymorphism that defines reactivity with alloantibodies generates an anchor for MHC class II peptide binding","volume":"158","author":"Wu","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.humimm.2024.111172_b0115","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jmb.2007.05.025","article-title":"Crystallographic structure of the human leukocyte antigen DRA, DRB3*0101: models of a directional alloimmune response and autoimmunity","volume":"371","author":"Parry","year":"2007","journal-title":"J Mol Biol"},{"key":"10.1016\/j.humimm.2024.111172_b0120","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood-2009-04-211839","article-title":"Naturally processed peptides spanning the HPA-1a polymorphism are efficiently generated and displayed from platelet glycoprotein by HLA-DRB3*0101-positive antigen-presenting cells","volume":"114","author":"Anani Sarab","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.humimm.2024.111172_b0125","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/j.1537-2995.2005.00188.x","article-title":"Characterization of the alloreactive helper T-cell response to the platelet membrane glycoprotein IIIa (integrin-\u03b23) in human platelet antigen-1a alloimmunized human platelet antigen-1b1b women","volume":"45","author":"Sukati","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.humimm.2024.111172_b0130","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1182\/blood-2008-09-178475","article-title":"T-cell responses associated with neonatal alloimmune thrombocytopenia: Isolation of HPA-1a-specific, HLA-DRB3*0101-restricted CD4+ T cells","volume":"113","author":"Ahlen","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.humimm.2024.111172_b0135","doi-asserted-by":"crossref","first-page":"677","DOI":"10.4049\/jimmunol.0801473","article-title":"Evidence for the specificity for platelet HPA-1a alloepitope and the presenting HLA-DR52a of diverse antigen-specific helper T cell clones from alloimmunized mothers","volume":"183","author":"Rayment","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.humimm.2024.111172_b0140","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86558","article-title":"T cell responses to human platelet antigen-1a involve a unique form of indirect allorecognition","volume":"1","author":"Ahlen","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.humimm.2024.111172_b0145","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2249.2005.02903.x","article-title":"Reactivity of T cells from women with antibodies to the human platelet antigen (HPA)-1a to peptides encompassing the HPA-1 polymorphism","volume":"142","author":"Jackson","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.humimm.2024.111172_b0150","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1182\/blood-2004-04-1257","article-title":"Integrins: Dynamic scaffolds for adhesion and signaling in platelets","volume":"104","author":"Shattil","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.humimm.2024.111172_b0155","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/0092-8674(89)90946-X","article-title":"Recognition of distinct adhesive sites on fibrinogen by related integrins on platelets and endothelial cells","volume":"58","author":"Cheresh","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.humimm.2024.111172_b0160","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","article-title":"Integrins: Bidirectional, allosteric signaling machines","volume":"110","author":"Hynes","year":"2002","journal-title":"Cell"},{"issue":"Suppl 1","key":"10.1016\/j.humimm.2024.111172_b0165","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1111\/jth.12915","article-title":"\u03b1IIb\u03b23: structure and function","volume":"13","author":"Coller","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.humimm.2024.111172_b0170","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/ATVBAHA.114.303411","article-title":"Targeting integrin and integrin signaling in treating thrombosis","volume":"35","author":"Estevez","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.humimm.2024.111172_b0175","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/CIRCRESAHA.122.322332","article-title":"Integrin-dependent cell-matrix adhesion in endothelial health and disease","volume":"132","author":"Aman","year":"2023","journal-title":"Circ Res"},{"key":"10.1016\/j.humimm.2024.111172_b0180","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ydbio.2003.12.010","article-title":"\u03b15\u03b21, \u03b1V\u03b23 and the platelet-associated integrin \u03b1IIb\u03b23 coordinately regulate adhesion and migration of differentiating mouse trophoblast cells","volume":"268","author":"Rout","year":"2004","journal-title":"Dev Biol"},{"key":"10.1016\/j.humimm.2024.111172_b0185","doi-asserted-by":"crossref","DOI":"10.1177\/0963689720965979","article-title":"Osteopontin promotes trophoblast invasion in the smooth muscle cell-endothelial co-culture at least via targeting integrin \u03b1V\u03b23","volume":"29","author":"Ke","year":"2020","journal-title":"Cell Transplant"},{"key":"10.1016\/j.humimm.2024.111172_b0190","doi-asserted-by":"crossref","first-page":"E9105","DOI":"10.1073\/pnas.1806205115","article-title":"Autonomous conformational regulation of \u03b23 integrin and the conformation-dependent property of HPA-1a alloantibodies","volume":"115","author":"Thinn","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.humimm.2024.111172_b0195","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1161\/ATVBAHA.116.307281","article-title":"Antiendothelial \u03b1V\u03b23 antibodies are a major cause of intracranial bleeding in fetal\/neonatal alloimmune thrombocytopenia","volume":"36","author":"Santoso","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.humimm.2024.111172_b0200","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000515703","article-title":"Maternal anti-HPA-1a antibodies increase endothelial cell apoptosis and permeability","volume":"58","author":"Dardik","year":"2021","journal-title":"J Vasc Res"},{"key":"10.1016\/j.humimm.2024.111172_b0205","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12958-017-0245-6","article-title":"Anti-human platelet antigen (HPA)-1a antibodies may affect trophoblast functions crucial for placental development: A laboratory study using an in vitro model","volume":"15","author":"Eksteen","year":"2017","journal-title":"Reprod Biol Endocrinol"},{"key":"10.1016\/j.humimm.2024.111172_b0210","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22136763","article-title":"Placental complement activation in fetal and neonatal alloimmune thrombocytopenia: An observational study","volume":"22","author":"de Vos","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.humimm.2024.111172_b0215","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.placenta.2021.07.291","article-title":"Platelet alloimmunization is associated with low grade chronic histiocytic intervillositis - A new link to a rare placental lesion?","volume":"112","author":"Nedberg","year":"2021","journal-title":"Placenta"},{"key":"10.1016\/j.humimm.2024.111172_b0220","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1055\/s-2001-15254","article-title":"Alloimmune thrombocytopenia in the fetus and newborn","volume":"27","author":"Bussel","year":"2001","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.humimm.2024.111172_b0225","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/vox.12725","article-title":"International Collaboration for Transfusion Medicine, Maternal HPA-1a antibody level and its role in predicting the severity of Fetal\/Neonatal Alloimmune Thrombocytopenia: A systematic review","volume":"114","author":"Kjaer","year":"2019","journal-title":"Vox Sang"},{"key":"10.1016\/j.humimm.2024.111172_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.jogoh.2022.102345","article-title":"Management of fetal and neonatal alloimmunization thrombocytopenia: About the Francophone working group on fetomaternal platelet alloimmunization","volume":"51","author":"Winer","year":"2022","journal-title":"J Gynecol Obstet Hum Reprod"},{"issue":"e1\u2013637","key":"10.1016\/j.humimm.2024.111172_b0235","first-page":"e9","article-title":"Long-term neurodevelopmental outcome in children after antenatal intravenous immune globulin treatment in fetal and neonatal alloimmune thrombocytopenia","volume":"637","author":"de Vos","year":"2022","journal-title":"Am J Obstet Gynecol 227"},{"key":"10.1016\/j.humimm.2024.111172_b0240","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: How does IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.humimm.2024.111172_b0245","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood","volume":"1","author":"Imbach","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.humimm.2024.111172_b0250","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1056\/NEJM198205273062102","article-title":"Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin","volume":"306","author":"Fehr","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humimm.2024.111172_b0255","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJM198811243192103","article-title":"Antenatal treatment of neonatal alloimmune thrombocytopenia","volume":"319","author":"Bussel","year":"1988","journal-title":"N Engl J Med."},{"key":"10.1016\/j.humimm.2024.111172_b0260","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.siny.2015.12.004","article-title":"Fetal and neonatal alloimmune thrombocytopenia","volume":"21","author":"Zdravic","year":"2016","journal-title":"Semin Fetal Neonatal Med"},{"key":"10.1016\/j.humimm.2024.111172_b0265","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/jcm6020016","article-title":"Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)","volume":"6","author":"Zufferey","year":"2017","journal-title":"J Clin Med"},{"key":"10.1016\/j.humimm.2024.111172_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2019.102710","article-title":"The use of IVIg in fetal and neonatal alloimmune thrombocytopenia - Principles and mechanisms","volume":"59","author":"Wabnitz","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.humimm.2024.111172_b0275","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1056\/NEJMoa2314466","article-title":"Nipocalimab in early-onset severe hemolytic disease of the fetus and newborn","volume":"391","author":"Moise","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humimm.2024.111172_b0280","first-page":"76","article-title":"Monoclonal antibody SZ-21 to platelet membrane glycoprotein IIIa [Chi]","volume":"67","author":"Ruan","year":"1987","journal-title":"Chung-Hua I Hsueh Tsa Chih"},{"key":"10.1016\/j.humimm.2024.111172_b0285","first-page":"195","article-title":"The antigenic site of monoclonal antibody SZ21, a fragment of platelet glycoprotein IIIa, and its relationship with chymotrypsin mediated platelet aggregation","volume":"19","author":"Du","year":"1987","journal-title":"Acta Biochimica et Biophysica Sinica"},{"key":"10.1016\/j.humimm.2024.111172_b0290","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1399-0039.1995.tb03129.x","article-title":"A monoclonal antibody (SZ21) specific for platelet GPIIIa distinguishes PlA1 from PlA2","volume":"46","author":"Weiss","year":"1995","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.humimm.2024.111172_b0295","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1182\/blood.V86.12.4430.bloodjournal86124430","article-title":"A human monoclonal antibody specific for the leucine-33 (P1A1, HPA-1a) form of platelet glycoprotein IIIa from a V gene phage display library","volume":"86","author":"Griffin","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.humimm.2024.111172_b0300","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1160\/TH03-07-0484","article-title":"The effect of recombinant IgG antibodies against the leucine-33 form of the platelet \u03b23 integrin (HPA-1a) on platelet function","volume":"91","author":"Joutsi-Korhonen","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.humimm.2024.111172_b0305","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1182\/bloodadvances.2018023341","article-title":"High-resolution mapping of the polyclonal immune response to the human platelet alloantigen HPA-1a","volume":"2","author":"Zhi","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.humimm.2024.111172_b0310","first-page":"2929","article-title":"Developing recombinant HPA-1a-specific antibodies with abrogated Fc receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia","volume":"118","author":"Ghevaert","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.humimm.2024.111172_b0315","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1182\/blood-2013-02-481887","article-title":"Recombinant HPA-1a antibody therapy for treatment of fetomaternal alloimmune thrombocytopenia: Proof of principle in human volunteers","volume":"122","author":"Ghevaert","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.humimm.2024.111172_b0320","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1537-2995.2008.01972.x","article-title":"Blockade of maternal anti-HPA-1a-mediated platelet clearance by an HPA-1a epitope-specific F(ab') in an in vivo mouse model of alloimmune thrombocytopenia","volume":"49","author":"Bakchoul","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.humimm.2024.111172_b0325","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood-2012-11-468561","article-title":"Inhibition of HPA-1a alloantibody-mediated platelet destruction by a deglycosylated anti-HPA-1a monoclonal antibody in mice: Toward targeted treatment of fetal-alloimmune thrombocytopenia","volume":"122","author":"Bakchoul","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.humimm.2024.111172_b0330","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1182\/blood.2022016376","article-title":"Antigen-guided depletion of anti-HLA antibody-producing cells by HLA-Fc fusion proteins","volume":"140","author":"Webber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.humimm.2024.111172_b0335","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.humimm.2024.111172_b0340","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3389\/fimmu.2019.01418","article-title":"Pemphigus: Current and future therapeutic strategies","volume":"10","author":"Didona","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.humimm.2024.111172_b0345","article-title":"Milestones in personalized medicine in Pemphigus and Pemphigoid","volume":"11","author":"Bieber","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.humimm.2024.111172_b0350","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14728214.2021.1952982","article-title":"Emerging drugs for the treatment of myasthenia gravis","volume":"26","author":"Menon","year":"2021","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.humimm.2024.111172_b0355","doi-asserted-by":"crossref","first-page":"e19763","DOI":"10.1016\/j.heliyon.2023.e19763","article-title":"Engineering chimeric autoantibody receptor T cells for targeted B cell depletion in multiple sclerosis model: An in-vitro study","volume":"9","author":"Sahlolbei","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.humimm.2024.111172_b0360","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1016\/j.cell.2023.10.001","article-title":"Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells","author":"Reincke","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.humimm.2024.111172_b0365","first-page":"2256","article-title":"GPIb\u03b1 CAAR-T cells function like a Trojan horse to eliminate autoreactive B cells to treat immune thrombocytopenia","volume":"109","author":"Zhou","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.humimm.2024.111172_b0370","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/MOH.0b013e328358f86c","article-title":"Towards a prophylactic treatment of HPA-related foetal and neonatal alloimmune thrombocytopenia","volume":"19","author":"Kjeldsen-Kragh","year":"2012","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.humimm.2024.111172_b0375","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1111\/j.1537-2995.2011.03480.x","article-title":"Toward a prophylaxis against fetal and neonatal alloimmune thrombocytopenia: Induction of antibody-mediated immune suppression and prevention of severe clinical complications in a murine model","volume":"52","author":"Tiller","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.humimm.2024.111172_b0380","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1111\/j.0041-1132.2003.00632.x","article-title":"Thirty-five years of Rh prophylaxis","volume":"43","author":"Bowman","year":"2003","journal-title":"Transfusion"},{"key":"10.1016\/j.humimm.2024.111172_b0385","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1097\/AOG.0000000000002528","article-title":"ACOG Practice Bulletin No. 192: Management of alloimmunization during pregnancy","volume":"131","author":"Holmgren","year":"2018","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.humimm.2024.111172_b0390","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/AOG.0000000000002226","article-title":"Practice Bulletin No. 181 Summary: Prevention of RhD alloimmunization","volume":"130","author":"Silver","year":"2017","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.humimm.2024.111172_b0395","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jtha.2022.11.041","article-title":"An HPA-1a-positive platelet-depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: A randomized, single-blind, placebo-controlled, single-center, phase 1\/2 proof-of-concept study","volume":"21","author":"Geisen","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.humimm.2024.111172_b0400","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.4049\/jimmunol.1401599","article-title":"Characterization of a human platelet antigen-1a-specific monoclonal antibody derived from a B cell from a woman alloimmunized in pregnancy","volume":"194","author":"Eksteen","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.humimm.2024.111172_b0405","doi-asserted-by":"crossref","unstructured":"C. Geisen, E. Fleck, S. Gast\u00f3n Sch\u00e4fer, C. Walter, S. Braeuninger, J. S\u00f8ndergaard Jensen, R. Armstrong, D. Sheridan, K. Patki, M. Kjaer, F. Behrens, E. Seifried, J. Kjeldsen-Kragh, M. K\u00f6hm, Dose-dependent elimination of HPA-1a platelets by subcutaneous RLYB212, a monoclonal antibody to prevent fetal and neonatal alloimmune thrombocytopenia, Research and Practice in Thrombosis and Haemostasis 7(Suppl 2) (2023) 100679.","DOI":"10.1016\/j.rpth.2023.100679"},{"key":"10.1016\/j.humimm.2024.111172_b0410","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1182\/blood.V85.11.3028.bloodjournal85113028","article-title":"Involvement of the cysteine-rich domain of glycoprotein IIIa in the expression of the human platelet alloantigen, PlA1: Evidence for heterogeneity in the humoral response","volume":"85","author":"Valentin","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.humimm.2024.111172_b0415","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1172\/JCI114082","article-title":"The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33\/Proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing","volume":"83","author":"Newman","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.humimm.2024.111172_b0420","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1182\/blood.V93.9.2959.409k20_2959_2967","article-title":"Construction of a human platelet alloantigen-1a epitope(s) within murine glycoprotein IIIa: Identification of residues critical to the conformation of the antibody binding site(s)","volume":"93","author":"Barron-Casella","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.humimm.2024.111172_b0425","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1182\/bloodadvances.2021004371","article-title":"Preclinical evaluation of immunotherapeutic regimens for fetal\/neonatal alloimmune thrombocytopenia","volume":"5","author":"Zhi","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.humimm.2024.111172_b0430","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4049\/immunohorizons.2100097","article-title":"Prevention of fetal\/neonatal alloimmune thrombocytopenia in mice: Biochemical and cell biological characterization of isoforms of a human monoclonal antibody","volume":"6","author":"Mortberg","year":"2022","journal-title":"Immunohorizons"},{"key":"10.1016\/j.humimm.2024.111172_b0435","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1182\/blood.2022015666","article-title":"Prophylactic administration of HPA-1a-specific antibodies prevents fetal\/neonatal alloimmune thrombocytopenia in mice","volume":"140","author":"Zhi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.humimm.2024.111172_b0440","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1182\/blood-2023-177657","article-title":"Identifying pregnancies at higher risk for HPA-1a alloimmunization and Fetal\/Neonatal Alloimmune Thrombocytopenia (FNAIT): An international, prospective, natural history study","volume":"142","author":"Haar","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.humimm.2024.111172_b0445","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1172\/JCI109038","article-title":"Deletion of the platelet-specific alloantigen PlA1 from platelets in Glanzmann's thrombasthenia","volume":"61","author":"Kunicki","year":"1978","journal-title":"J Clin Invest"},{"key":"10.1016\/j.humimm.2024.111172_b0450","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0161-5890(79)90100-7","article-title":"Isolation and immunologic characterization of the human platelet alloantigen, P1A1","volume":"16","author":"Kunicki","year":"1979","journal-title":"Mol Immunol"},{"key":"10.1016\/j.humimm.2024.111172_b0455","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1182\/blood.2021011131","article-title":"Successful prenatal therapy for anti-CD36-mediated severe FNAIT by deglycosylated antibodies in a novel murine model","volume":"138","author":"Xu","year":"2021","journal-title":"Blood"}],"container-title":["Human Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019888592400435X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019888592400435X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T01:37:07Z","timestamp":1733881027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019888592400435X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":91,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S019888592400435X"],"URL":"https:\/\/doi.org\/10.1016\/j.humimm.2024.111172","relation":{},"ISSN":["0198-8859"],"issn-type":[{"value":"0198-8859","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antigen-specific immunotherapy for platelet alloimmune disorders","name":"articletitle","label":"Article Title"},{"value":"Human Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humimm.2024.111172","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of American Society for Histocompatibility and Immunogenetics.","name":"copyright","label":"Copyright"}],"article-number":"111172"}}